异位骨化的脱轨和 RAR 的启动。
Derailing heterotopic ossification and RARing to go.
出版信息
Nat Med. 2011 Apr;17(4):420-1. doi: 10.1038/nm0411-420.
Abstract
Retinoic acid receptors inhibit chondrogenesis, but their ability to block the cartilaginous scaffold of heterotopic endochondral ossification has not been explored. A study in mice shows that agonists of retinoic acid receptor-γ potently inhibit heterotopic endochondral ossification, suggesting therapeutic potential in people with this condition (pages 454–460).
摘要
维甲酸受体抑制软骨生成，但它们阻断异位软骨内骨化软骨支架的能力尚未得到探索。一项在小鼠中的研究表明，维甲酸受体-γ激动剂能强烈抑制异位软骨内骨化，这表明它们在这种情况下对人类具有治疗潜力（第 454-460 页）。
相似文献
1
Derailing heterotopic ossification and RARing to go.
Nat Med. 2011 Apr;17(4):420-1. doi: 10.1038/nm0411-420.
2
Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-γ agonists.
Nat Med. 2011 Apr;17(4):454-60. doi: 10.1038/nm.2334. Epub 2011 Apr 3.
3
Retinoid Agonists in the Targeting of Heterotopic Ossification.
Cells. 2021 Nov 19;10(11):3245. doi: 10.3390/cells10113245.
4
Inhibition of ectopic bone formation by a selective retinoic acid receptor alpha-agonist: a new therapy for heterotopic ossification?
J Orthop Res. 2010 Feb;28(2):271-7. doi: 10.1002/jor.20985.
5
Tamoxifen Inhibits the Progression of Trauma-Induced Heterotopic Ossification in Mice.
Med Sci Monit. 2019 Oct 21;25:7872-7881. doi: 10.12659/MSM.916733.
6
Targeted stimulation of retinoic acid receptor-γ mitigates the formation of heterotopic ossification in an established blast-related traumatic injury model.
Bone. 2016 Sep;90:159-67. doi: 10.1016/j.bone.2016.06.014. Epub 2016 Jun 28.
7
Neurotrophin-3 acts on the endothelial-mesenchymal transition of heterotopic ossification in rats.
J Cell Mol Med. 2019 Apr;23(4):2595-2609. doi: 10.1111/jcmm.14150. Epub 2019 Jan 22.
8
Inflammation in Fibrodysplasia Ossificans Progressiva and Other Forms of Heterotopic Ossification.
Curr Osteoporos Rep. 2019 Dec;17(6):387-394. doi: 10.1007/s11914-019-00541-x.
9
Inhibition of Hif1α prevents both trauma-induced and genetic heterotopic ossification.
Proc Natl Acad Sci U S A. 2016 Jan 19;113(3):E338-47. doi: 10.1073/pnas.1515397113. Epub 2015 Dec 31.
10
Gli1-labeled adult mesenchymal stem/progenitor cells and hedgehog signaling contribute to endochondral heterotopic ossification.
Bone. 2018 Apr;109:71-79. doi: 10.1016/j.bone.2017.06.014. Epub 2017 Jun 21.
引用本文的文献
1
Palovarotene Can Attenuate Heterotopic Ossification Induced by Tendon Stem Cells by Downregulating the Synergistic Effects of Smad and NF-B Signaling Pathway following Stimulation of the Inflammatory Microenvironment.
Stem Cells Int. 2022 Apr 28;2022:1560943. doi: 10.1155/2022/1560943. eCollection 2022.
2
Challenges and Opportunities for Drug Repositioning in Fibrodysplasia Ossificans Progressiva.
Biomedicines. 2021 Feb 19;9(2):213. doi: 10.3390/biomedicines9020213.
3
Hypoxia-selective allosteric destabilization of activin receptor-like kinases: A potential therapeutic avenue for prophylaxis of heterotopic ossification.
Bone. 2018 Jul;112:71-89. doi: 10.1016/j.bone.2018.03.027. Epub 2018 Apr 5.
4
From mysteries to medicines: drug development for fibrodysplasia ossificans progressive.
Expert Opin Orphan Drugs. 2013 Aug;1(8):637-649. doi: 10.1517/21678707.2013.825208.
5
Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons.
Pediatr Endocrinol Rev. 2013 Jun;10 Suppl 2(0 2):437-48.
6
The skeleton in the closet.
Gene. 2013 Oct 1;528(1):7-11. doi: 10.1016/j.gene.2013.06.022. Epub 2013 Jun 25.
7
Fibrodysplasia ossificans progressiva: mechanisms and models of skeletal metamorphosis.
Dis Model Mech. 2012 Nov;5(6):756-62. doi: 10.1242/dmm.010280.
8
Fibrodysplasia ossificans progressiva: a blueprint for metamorphosis.
Ann N Y Acad Sci. 2011 Nov;1237:5-10. doi: 10.1111/j.1749-6632.2011.06195.x.
本文引用的文献
1
Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-γ agonists.
Nat Med. 2011 Apr;17(4):454-60. doi: 10.1038/nm.2334. Epub 2011 Apr 3.
2
Conversion of vascular endothelial cells into multipotent stem-like cells.
Nat Med. 2010 Dec;16(12):1400-6. doi: 10.1038/nm.2252. Epub 2010 Nov 21.
3
Retinoic acid regulates bone morphogenic protein signal duration by promoting the degradation of phosphorylated Smad1.
Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18886-91. doi: 10.1073/pnas.1009244107. Epub 2010 Oct 18.
4
Inherited human diseases of heterotopic bone formation.
Nat Rev Rheumatol. 2010 Sep;6(9):518-27. doi: 10.1038/nrrheum.2010.122. Epub 2010 Aug 10.
5
Applications of small molecule BMP inhibitors in physiology and disease.
Cytokine Growth Factor Rev. 2009 Oct-Dec;20(5-6):409-18. doi: 10.1016/j.cytogfr.2009.10.021. Epub 2009 Nov 14.
6
The FOP metamorphogene encodes a novel type I receptor that dysregulates BMP signaling.
Cytokine Growth Factor Rev. 2009 Oct-Dec;20(5-6):399-407. doi: 10.1016/j.cytogfr.2009.10.006. Epub 2009 Nov 6.
7
Wnt/beta-catenin and retinoic acid receptor signaling pathways interact to regulate chondrocyte function and matrix turnover.
J Biol Chem. 2010 Jan 1;285(1):317-27. doi: 10.1074/jbc.M109.053926. Epub 2009 Oct 26.
8
Retinoic acid enhances skeletal muscle progenitor formation and bypasses inhibition by bone morphogenetic protein 4 but not dominant negative beta-catenin.
BMC Biol. 2009 Oct 8;7:67. doi: 10.1186/1741-7007-7-67.
9
BMP action in skeletogenesis involves attenuation of retinoid signaling.
J Cell Biol. 2006 Jul 3;174(1):101-13. doi: 10.1083/jcb.200604150.
10
A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva.
Nat Genet. 2006 May;38(5):525-7. doi: 10.1038/ng1783. Epub 2006 Apr 23.
Zotero 插件